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A Virtuous Cycle Turns*Richard J. Kovacs, MDSEE PAGE 1224C linicians face many questions in daily prac-tice; among the most important are: Doesthe evidence upon which I base my practice
produce the desired results in the patients I care for?
Am I doing my part to reduce racial and ethnic dispar-
ities in care?
The Institute of Medicine, in a report on the
“Learning Healthcare System,” has called attention to
the virtuous cycle of an evidence-based practice that
in turn generates practice-based evidence of patient
outcomes (1). Clinicians need more opportunities to
look at their own practice-based evidence, reﬂect on
the evidence, and improve care. This is the essence of
the learning health care system. Electronic medical
records and other sources of “big data” now allow for
the analysis of such practice level data, including
outcomes of patients treated according to different
pathways. These data hold promise to not only
conﬁrm guideline adherence in real-world care, but
also identify gaps in care and generate new hypoth-
eses for testing in randomized trials. The sheer
volume of practice-based evidence that can be accu-
mulated automatically should allow for a rapid cycle
of improvement in care and the acquisition of new
knowledge. The practice of medicine and the pursuit
of new knowledge will merge in ways not possible
prior to electronic health records and big data (2,3)
(Figure 1).
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paper to disclose.clinicians when they apply the results of randomized
trials in 1 population to the patients they care for who
may not “look like” the trial participants. In cardio-
vascular medicine, these racial and ethnic differences
must be dealt with every day when treating common
diseases, such as hypertension and heart failure
(HF). It has been more than 5 years since the Amer-
ican College of Cardiology called for a Coalition to
Reduce Racial and Ethnic Disparities in Cardiovascu-
lar Disease Outcomes (CREDO) (4). CREDO promoted
strategies of performance measure–based quality
improvement, provider cultural competence training,
team-based care, and patient education. Perhaps we
can add 1 more strategy: the effective use of elec-
tronic records and big data.In this issue of the Journal, Ogedegbe et al. (5)
address both of the previously mentioned questions
in an analysis of real-world clinical data on the
treatment of hypertensive black patients served by
New York City’s Health and Hospital Corporation. The
data come from a broad sample of care sites: acute
care hospitals, long-term care facilities, home care
services, and neighborhood clinics. More than 43,000
patient records were analyzed to answer a crucial
question of comparative effectiveness: Did black hy-
pertensive patients receiving angiotensin-converting
enzyme (ACE) inhibitors in this health care system
fare worse than white hypertensive patients receiving
ACE inhibitors?
They determined that ACE inhibitor use in blacks
was associated with poorer outcomes: more strokes,
myocardial infarctions, and HF. Comparing the
effectiveness and safety of antihypertensive drugs in
real-world practice empowers a large system of care
to make changes that will prevent adverse events.
The opportunity to improve outcomes is staggering.
FIGURE 1 Evidence-Based Practice and Practice-Based
Evidence
Evidence-Based Practice
Practice-Based Evidence
A learning health care system continuously evaluates the evi-
dence generated from patient care and feeds information back to
the system to improve performance and close gaps in quality.
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1235In this study, 12,937 blacks in the health care system
were treated with ACE inhibitors and nearly 84%
were on monotherapy. Presumably, these patients’
blood pressure could be controlled with 1 to 2 alter-
native antihypertensive agents after simple educa-
tion of the front-line providers about the results of
this trial. Using the number of events reported in the
paper, 13 strokes, 3 heart attacks, and 25 cases of HF
might be prevented over a period of about 5 years at
little or no cost to the system. The long-term sequelae
of those events also could be avoided. In additionto the health beneﬁts to the patients, signiﬁcant
savings to the health care system should follow.
Demonstrating such a reduction in stroke, myocardial
infarction, and HF would seem to be a logical next
step for this health care system.
The results may be generalizable and applied to
reduce risk in other health care systems. The authors
point out that the racial and ethnic mix of New York
City is similar to many cities across the United States;
consequently, if the data here were applied in similar
health care systems, we could rapidly close a gap in
care with minimal resource consumption. The evi-
dence generated by this practice enables the virtuous
cycle envisioned by the Institute of Medicine to go
forward another turn. We look forward to data
demonstrating that outcomes can be improved if the
care team applies the results of this important anal-
ysis to treatment of black patients cared for by the
New York City’s Health and Hospital Corporation, a
learning health care system.
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